126 related articles for article (PubMed ID: 8520164)
1. Effects of medroxyprogesterone acetate therapy on advanced or recurrent breast cancer and its influences on blood coagulation and the fibrinolytic system.
Abe O; Asaishi K; Izuo M; Enomoto K; Koyama H; Tominaga T; Nomura Y; Ohshima A; Aoki N; Tsukada T
Surg Today; 1995; 25(8):701-10. PubMed ID: 8520164
[TBL] [Abstract][Full Text] [Related]
2. Effects of chemoendocrine therapy on the coagulation-fibrinolytic systems in patients with advanced breast cancer. Japan Advanced Breast Cancer Study Group and Japan Clinical Oncology Group.
;
Jpn J Cancer Res; 1993 Apr; 84(4):455-61. PubMed ID: 8514613
[TBL] [Abstract][Full Text] [Related]
3. Effect of high-dose progestogen on hemostatic properties of blood in patients with endometrial cancer.
Kaibara M; Watanabe T; Ooka F; Liang SG; Aisaka K; Okinaga S
Clin Hemorheol Microcirc; 2001; 24(2):93-9. PubMed ID: 11381184
[TBL] [Abstract][Full Text] [Related]
4. Comparison of chemotherapy with or without medroxyprogesterone acetate for advanced or recurrent breast cancer.
Tominaga T; Abe O; Ohshima A; Hayasaka H; Uchino J; Abe R; Enomoto K; Izuo M; Watanabe H; Takatani O
Eur J Cancer; 1994; 30A(7):959-64. PubMed ID: 7946592
[TBL] [Abstract][Full Text] [Related]
5. [Study on CAF + medroxyprogesterone acetate (MPA) therapy for advanced or recurrent breast cancer--comparison between MPA 600 mg and 1,200 mg. Kyushu CAFT Therapy Study Group (Third Study)].
Mitsuyama S; Ohno S; Koga T; Takayama T; Yamashita J; Ogawa M; Shirouzu K; Sugimachi K; Nomura Y; Ogawa N
Gan To Kagaku Ryoho; 1999 Nov; 26(13):2029-36. PubMed ID: 10584567
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant chemohormonal therapy with cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) with or without medroxyprogesterone acetate for node-positive breast cancer patients.
Hupperets PS; Wils J; Volovics L; Schouten L; Fickers M; Bron H; Schouten HC; Jager J; Smeets J; de Jong J
Ann Oncol; 1993 Apr; 4(4):295-301. PubMed ID: 8518219
[TBL] [Abstract][Full Text] [Related]
7. A randomized controlled comparative study of oral medroxyprogesterone acetate 1,200 and 600 mg in patients with advanced or recurrent breast cancer.
Koyama H; Tominaga T; Asaishi K; Abe R; Iino Y; Enomoto K; Miura S; Nomura Y; Nakazato H; Abe O
Oncology; 1999; 56(4):283-90. PubMed ID: 10343191
[TBL] [Abstract][Full Text] [Related]
8. Changes in hematologic parameters during treatment with medroxyprogesterone acetate for breast cancer.
Yamamoto H; Noguchi S; Miyauchi K; Inaji H; Imaoka S; Koyama H; Iwanaga T
Jpn J Cancer Res; 1991 Apr; 82(4):420-5. PubMed ID: 1828463
[TBL] [Abstract][Full Text] [Related]
9. [Medroxyprogesterone acetate for treatment of advanced breast cancers].
Mitsuyama S; Anan K
Nihon Rinsho; 2000 Apr; 58 Suppl():317-21. PubMed ID: 11026012
[No Abstract] [Full Text] [Related]
10. [Comparison of CAF plus MPA with CAF plus TAM for advanced or recurrent breast cancer--Kyushu CAFT Study Group of Advanced or Recurrent Breast Cancer].
Mitsuyama S; Tashiro H; Koga T; Maehara Y; Ogawa M; Kakegawa T; Shimazu H; Sugimachi K; Tomita M; Nakamura Y
Gan To Kagaku Ryoho; 1995 Dec; 22(14):2073-80. PubMed ID: 8607618
[TBL] [Abstract][Full Text] [Related]
11. Effects on blood coagulation of adjuvant CNF (cyclophosphamide, novantrone, 5-fluorouracil) chemotherapy in stage II breast cancer patients.
Pectasides D; Tsavdaridis D; Aggouridaki C; Tsavdaridou V; Visvikis A; Tsatalas K; Fountzilas G
Anticancer Res; 1999; 19(4C):3521-6. PubMed ID: 10629646
[TBL] [Abstract][Full Text] [Related]
12. [Effect of high-dose medroxyprogesterone acetate on coagulative and fibrinolytic factors in patients with gynecological cancers].
Ishizaki T; Itoh R; Yasuda J; Yamamoto T; Okada H
Gan To Kagaku Ryoho; 1992 Jun; 19(6):837-42. PubMed ID: 1534983
[TBL] [Abstract][Full Text] [Related]
13. Multidrug-resistant recurrent breast cancer which responded to medroxyprogesterone acetate showing a remarkable improvement in the quality of life: report of a case and the role of team medical care.
Kurihara T; Higashi Y; Suemasu K; Tabei T; Ishiguro S; Iino Y; Morishita Y; Takeda F
Surg Today; 1998; 28(9):979-84. PubMed ID: 9744415
[TBL] [Abstract][Full Text] [Related]
14. [Two cases of advanced breast cancer effectively treated with chemoendocrine therapy and radiotherapy].
Kimura M; Hagiwara S; Hirose K; Shimokawa Y; Iwai K; Uemura K
Gan To Kagaku Ryoho; 1994 Oct; 21(14):2505-8. PubMed ID: 7944499
[TBL] [Abstract][Full Text] [Related]
15. [A case of breast cancer with multiple organ metastases responding remarkably to combination therapy of CAF (cyclophosphamide, adriamycin and 5-FU), 5'-DFUR and MPA (medroxyprogesterone acetate)].
Maruyama S; Okumoto T; Kawasaki K; Ino H; Kanaya Y; Otani J; Yokoyama N; Soda M
Gan To Kagaku Ryoho; 2000 Dec; 27(14):2235-8. PubMed ID: 11142168
[TBL] [Abstract][Full Text] [Related]
16. [Clinical evaluation of adriamycin in advanced and recurrent breast cancer (No. 4)--Joint study by 30 institutes on the duration of remission using various maintenance therapies in patients treated with CAF. Clinical Study Group of Adriamycin for Breast Cancer in Japan].
Nomura Y; Abe O; Izuo M; Inoue K; Enomoto K; Kubo K; Koyama H; Sakai K; Terasawa T; Tominaga T
Gan To Kagaku Ryoho; 1988 Jun; 15(6):1863-71. PubMed ID: 3382238
[TBL] [Abstract][Full Text] [Related]
17. Mitomycin C + high-dose medroxyprogesterone versus cyclophosphamide+doxorubicin plus fluorouracil as first-line treatment for metastatic breast cancer.
Falkson CI; Falkson G; Falkson CB; Falkson HC
Oncology; 1992; 49(6):418-21. PubMed ID: 1465278
[TBL] [Abstract][Full Text] [Related]
18. [A case report of advanced breast cancer with remarkable response to chemoendocrine therapy (CTF + MPA)].
Yokota T; Fujii T; Roppongi T; Kanno K; Ogata T
Gan To Kagaku Ryoho; 1998 Apr; 25(5):739-42. PubMed ID: 9571973
[TBL] [Abstract][Full Text] [Related]
19. [Administration method and recurrence-preventing effect of medroxyprogesterone acetate (MPA) as a postoperative adjuvant endocrine therapy for stage III breast cancer. Kitakyushu Collaborative Study Group for Breast Cancer].
Mitsuyama S; Kuroda Y; Ohsato K; Nakamura Y; Murakami F; Nishikata F; Ikeda S; Egami T; Mori A; Ohe H
Gan To Kagaku Ryoho; 1996 Aug; 23(9):1153-60. PubMed ID: 8751803
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant chemo-hormonal therapy with cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) with or without medroxyprogesterone acetate for node-positive cancer patients. Update at 7-year follow-up.
Hupperets P; Wils J; Volovics L; Schouten L; Fickers M; Bron H; Schouten H; Jager J; de Jong J; Beex L
Ann Oncol; 1995 Jan; 6(1):90-1. PubMed ID: 7710989
[No Abstract] [Full Text] [Related]
[Next] [New Search]
